natgillin/translations-raw huggingface dataset:
Barnet skal tage den beregnede dosis af PREZISTA og ritonavir 2 gange dagligt eller 1 gang dagligt.
The child must take the appropriate doses of PREZISTA and ritonavir two times per day or once a day.
Barnet skal tage den beregnede dosis af PREZISTA og ritonavir 2 gange dagligt eller en gang dagligt.
The child must take the appropriate doses of PREZISTA and ritonavir two times per day or once a day.
Barnet skal tage PREZISTA sammen med mad.
The child must take PREZISTA with food.
Barnet skal undgå voldsom fysisk udfoldelse, navnlig i varmt vejr
The child must avoid heavy exercise especially when the weather is hot
Barnet skal undgå voldsom fysisk udfoldelse, navnlig i varmt vejr
your child must avoid heavy exercise especially when the weather is hot
Barnets hud skal holdes kølig med vand
Keep the child's skin cool with water
Barnets læge fastlægger den korrekte dosis til dit barn.
Your child’s doctor will determine the appropriate dosing regimen for your child.
Barnets læge fastsætter den korrekte dosis til dit barn.
Your child’s doctor will determine the appropriate dosing regimen for your child.
Barnets læge fastsætter den rette behandling til dit barn.
Your child’s doctor will determine the appropriate dosing regimen for your child.
Barnets læge vil fortælle dig den korrekte dosis.
The doctor will tell you the correct dose to use.
Barnets læge vil fortælle dig den korrekte dosis.
Your child’s doctor will tell you the correct dose to use.
Barnets læge vil hjælpe dig med at beslutte, om dit barn bør få Thyrogen.
Your child’s doctor will help you decide if Thyrogen should be given to your child.
Barnets symptomer kan komme igen efter ophør.
Your child’s symptoms may return upon discontinuation.
Barnets vejrtrækning bliver langsommere eller stopper, f.eks. langsom eller overfladisk vejrtrækning eller blå læber
The child’s breathing slows down or stops e.g. slow or shallow breathing or blue lips
Barnets vægt (nærmeste)
Child’s weight (nearest)
Barnets vægt i kg
Body weight of your child
Basal celle karcinom
Basal cell carcinoma
Basal insulindosis (IE/dag) ved uge 78
Basal insulin dose (IU/day) at week 78
basalcellekarcinom,
All ADRs/Frequency
Basalcellekarcinom-diagnosen blev bekræftet histologisk inden inklusion i studiet.
Prior to study enrolment, diagnosis of BCC was confirmed by histology.
Basalinsulin (enheder)
Basal insulin (units)
Basalinsulin kaldet insulin degludec – det har en langvarig blodsukkersænkende virkning.
Basal insulin called insulin degludec – this has a long blood-sugar-lowering effect.
Basalinsulin og sulfonylurinstof/glinider blev seponeret ved randomisering.
Basal insulin and sulphonylurea/glinides were discontinued at randomisation.
Basalinsulindosisc (U/kg)
Basal insulin dosec (U/kg)
Basalkomponenten i Ryzodeg (insulin degludec) danner efter subkutan injektion opløselige multihexamerer, hvorved der opstår et depot, hvorfra insulin degludec kontinuerligt og langsomt absorberes i kredsløbet og fører til den flade og stabile glucosesænkende virkning af Ryzodeg.
The basal component of Ryzodeg (insulin degludec) forms soluble multi-hexamers upon subcutaneous injection, resulting in a depot from which insulin degludec is continuously and slowly absorbed into the circulation leading to a flat and stable glucose-lowering-effect.
Basalt antralt follikelantal> 20.
A basal antral follicle count > 20.
BASDAI-50(c,d)
BASDAI 50(c,d)
Basedows sygdom
Basedow’s disease
Basedows sygdom, hypertyreoidisme, autoimmun tyreoiditis, hypotyreoidisme, struma, antityreoid-antistof- positiv
Basedow’s disease, hyperthyroidism, autoimmune thyroiditis, hypothyroidism, goitre, anti-thyroid antibody positive
baseline
0.04
Baseline
37%†,
Baseline
Baseline (mean)
Baseline
Value
baseline
≥ 100,000
Baseline % CD4+ celler
Baseline % CD4+ cells
Baseline (gennem- snit) n = 503
Baseline (mean) n=503
Baseline (gennem- snit) n = 505
Baseline (mean) n=505
Baseline (gennemsnit)
Baseline (Mean)
Baseline (gennemsnit)
Baseline (mean) in kg
Baseline (gennemsnit) Ændring fra baselined Forskel fra placebod (95 % CI)
Baseline (mean) Change from baselined Difference from placebod (95% CI)
Baseline (gennemsnitlig)
Adjusted for baseline
Baseline (gennemsnitlig)
Baseline (mean)
Baseline (gennemsnitlig)
Baseline (mean) Change from baselinec
Baseline (gennemsnitlig) 7,92 8,11 Ændring fra
Baseline (mean) Change from baselinec Difference from placeboc
Baseline (gennemsnitlig) Ændring fra baselinec
Baseline (mean) Change from baselinec
Baseline (gennemsnitligt)
Baseline (mean)
Baseline (gennemsnitligt) Ændring fra baselinec
Baseline (mean) Change from baselinec
Baseline (m)
Baseline (m) [SD]
Baseline (middel)
Baseline (mean) Change at Week 52b
Baseline (middel) Ændring ved uge 52b
Baseline (mean)
Baseline (middel- værdi)
Baseline (mean)
Baseline (middelværdi) i kg
Baseline (mean) in kg
Baseline 1,7 1,7 1,8
Baseline 1.7 1.7 1.8
baseline = uge 0
baseline = week 0
Baseline ADHD-RS-IV (SD)
Baseline ADHD-RS- IV (SD)
Baseline af antallet af CD-19 positive celletal og størrelsen af målte tumorbyrde, forklarer noget af variationen i CL2 af MabThera fra 161 patienter, som fik 375 mg/m2 ugentlig i 4 uger som intravenøs infusion.
Baseline CD19-positive cell counts and size of measurable tumour lesions contributed to some of the variability in CL2 of MabThera in data from 161 patients given 375 mg/m2 as an intravenous infusion for 4 weekly doses.
Baseline ALAT > 2 x ULN
Baseline ALT > 2 x ULN
Baseline ALAT ≤ 1 x ULN2
Baseline ALT ≤ 1 x ULN2
Baseline ANC  1.500/mm3 ved den første administration, baseline ANC  1.000/mm3 ved efterfølgende administrationer.
Baseline ANC  1,500/mm3 for the first administration, baseline ANC  1,000/mm3 for subsequent administrations (see section 4.4).
baseline blev fjernet. c Median procent (%) reduktion af aktinisk keratose-læsioner i forhold til baseline. d p<0.001; sammenlignet med vehikel ved logistisk regression med behandling, studie og anatomisk placering.
actinic keratosis lesions were cleared. c Median percent (%) reduction in actinic keratosis lesions compared to baseline. d p<0.001; compared to vehicle by logistic regression with treatment, study and anatomical location.
Baseline CD4+ (celler/mm3)
Baseline CD4+ (cells/mm3)
Baseline CD4+-celletal ≤ 200 celler/mm3
Baseline CD4+ Cell Count ≤200 cells/mm3
Baseline creatinin clearance (ml/min)
Baseline creatinine clearance (ml/min)
Baseline DARUNAVIR FCb
Baseline DRV FCb
Baseline ferritin (middel ± SD, ng/ml)
Baseline ferritin (mean ± SD, ng/ml)
Baseline Gennemsnitlig ændring
Baseline Average change
Baseline HBV-DNA
Baseline HBV DNA
Baseline HCV-rnaa
Baseline HCV RNAa
Baseline karakteristik for patienter 12 – 18 år, som fik kapsler
Baseline characteristics for patients 12 – 18 years of age who took capsule
Baseline karakteristika
Baseline Characteristics
Baseline kreatin clearance (ml/min)
Baseline creatinine clearance (ml/min)
Baseline kreatinin clearance (ml/min) Anbefalet dosis af Zoledronsyre Actavis*
Baseline Creatinine Clearance (ml/min) Zoledronic acid Actavis recommended dose
Baseline kreatinin clearance (ml/min) Anbefalet dosis af Zoledronsyre Teva*
Baseline Creatinine Clearance (ml/min) Zoledronic acid Teva Recommended Dose
Baseline kreatinin clearance (ml/min) Zoledronsyre Hospira anbefalet dosis*
Baseline creatinine clearance (ml/min) Zoledronic Acid Hospira recommended dose
Baseline kreatinin- clearance (ml/min)
Baseline creatinine clearance (ml/min)
Baseline kreatininclearance (ml/min) Anbefalet dosis af zoledronsyre*
Baseline Creatinine Clearance (ml/min) Zoledronic acid recommended dose
Baseline LDH (enheder/l), middelværdi (standardafvigelse)
Baseline LDH (U/L), mean (SD)
Baseline plasmaniveauerne skal måles på grund af en øget risiko for toksicitet, hvis
That baseline plasma levels may need measuring because of an increased risk of toxicity if
Baseline scoreb
63.2% †,
Baseline sygdomskarakteristika
Baseline disease characteristics
Baseline til uge 24
Baseline to week 24
baseline til ≤ 7,5 mg/dag i løbet af uge 40 til og med uge
Prednisone reduction by ≥25% from baseline to ≤7.5 mg/day during weeks 40 through 52* (%)
Baseline trombocyttal (× 109/l), middelværdi (standardafvigelse)
Baseline platelet count (× 109/L), mean (SD)
Baseline trombocyttal, median ( 109/l)
Baseline platelet count, median ( 109/L)
Baseline TSAT (middel ± SD, %)
Baseline TSAT (mean ± SD, %)
Baseline virus- mængder
Baseline Viral Load
Baseline virusbelastning
Baseline Viral Load
Baseline vægt (kg)
Baseline weight (kg)
Baseline værdi (±SD)
Baseline value (±SD)
Baseline, gennemsnit
Baseline, mean
Baseline, gennemsnit (SD)
Baseline, mean (SD)
Baseline, Studiets afsl. og ændringsværdier er observeret Sidste observation fremført.
Baseline, End of trial and change values are observed Last observation carried forward.
Baseline-alder og baseline- kropsvægt er identificeret som statistisk signifikante covariater for henholdsvis cobimetinib-clearance og fordelingsvolumen.
Baseline age and baseline body weight were identified as statistically significant covariates on cobimetinib clearance and volume of distribution respectively.
Baseline-CD4-kategori 101-200
Baseline CD4 category 101-200
Baseline-CD4-kategori 201-350
Baseline CD4 category 201-350
Baseline-CD4-kategori 50-100
Baseline CD4 category 50-100
Baseline-CD4-kategori > 350
Baseline CD4 category >350
Baseline-CgA Baseline-NSE
Baseline CgA Baseline NSE
Baseline-clearance var 77 ml/min med et distributionsvolumen ved steady-state (Vss) på 2,6 l; halveringstiden var 55 minutter.
Baseline clearance was 77 ml/min with a volume of distribution at steady-state (Vss) of 2.6 l; half-life was 55 min.
Baseline-DARUNAVIR FCb
Baseline DRV FCb
Baseline-demografien var sammenlignelig mellem lenalidomidarmen og kontrolarmen.
The baseline demographic were comparable between the lenalidomide arm and control arm.
Baseline-eGFR (ml/min/1,73 m2), median (min.; maks)
Baseline eGFR (mL/min/1.73 m2 ), median (min, max)
Baseline-eGFR (ml/min/1,73 m2), median (min.; maks.)
Baseline eGFR (mL/min/1.73m2), median (min, max)
Baseline-fenylalaninniveauet i blodet i den Kuvan- behandlede gruppe og i placebogruppen var sammenlignelig med en middel ± SD baseline-værdi på henholdsvis 843 ± 300 µmol/l og 888 ± 323 µmol/l.
The baseline blood phenylalanine levels for the Kuvan-treated group and the placebo group were similar, with mean ± SD baseline blood phenylalanine levels of 843 ± 300 μmol/l and 888 ± 323 μmol/l, respectively.
Baseline-gennemsnit (SD)
Baseline mean (SD)
Baseline-genotype og darunavir FC (skift i følsomhed i forhold til reference) blev vist at være en forudsigende faktor for virologisk udfald.
Baseline genotype and darunavir FC (shift in susceptibility relative to reference) were shown to be a predictive factor of virologic outcome.
Baseline-hiv-1-RNA <
Baseline HIV-1 RNA
Baseline-hiv-1-RNA ≥
Baseline HIV-1 RNA
Baseline-hiv-1-virus- belastningsstratum (kopier/ml)
Baseline HIV−1 viral load stratum (copies/ml)
Baseline-karakteristika for de 81 patienter, der blev evalueret i de primære og sekundære effektanalyser fra de kombinerede studier, var (middel ± SD): kronologisk alder (år): 6,8  3,8; højde (cm): 84,1  15,8; højde standardafvigelse score (SDS): -6,9  1,8; væksthastighed (cm/år): 2,6  1,7; væksthastighed-SDS: -3,4  1,6; IGF-1 (ng/ml): 24,5  27,9; IGF-1 SDS: -4,2  2,0; og knoglealder (år): 3,8  2,8.
Baseline characteristics for the 81 patients evaluated in the primary and secondary efficacy analyses from the combined studies were (mean ± SD): chronological age (years): 6.8  3.8; height (cm): 84.1  15.8; height standard deviation score (SDS): -6.9  1.8; height velocity (cm/yr): 2.6  1.7; height velocity SDS: -3.4  1.6; IGF-1 (ng/ml): 24.5  27.9; IGF-1 SDS: -4.2  2.0; and bone age (years):
baseline-karakteristika for disse 50 patienter var generelt sammenlignelige med demografiske data og baseline-karakteristika for patienter, som fik 12 ugers studiebehandling.
Demographic and baseline characteristics of these 50 patients were generally comparable to those for patients who received 12 weeks of study treatment.
Baseline-karakteristika var ligeligt fordelt mellem de to behandlingsgrupper med hensyn til alder (gennemsnitslader var 46 år for SPRYCEL-gruppen og 49 år for imatinib-gruppen med henholdsvis 10% og 11% af patienterne på 65 år eller derover), køn (henholdsvis 44% og 37% kvinder) og race (kaukasisk 51% og 55%, asiatisk 42% og 37%).
Baseline characteristics were well balanced between the two treatment groups with respect to age (median age was 46 years for the SPRYCEL group and 49 years for the imatinib group with 10% and 11% of patients 65 years of age or older, respectively), gender (women 44% and 37%, respectively), and race (Caucasian 51% and 55%; Asian 42% and 37%, respectively).
Baseline-karakteristika var velbalancerede grupperne imellem undtagen andelen af patienter, som havde hjernemetastaser i anamnesen (19% og 13% i henholdsvis nivolumabgruppen og kemoterapigruppen) og patienter med LDH ved baseline, som var højere end ULN (henholdsvis 51% og 35%).
Baseline characteristics were balanced between groups except for the proportions of patients who had a history of brain metastasis (19% and 13% in the nivolumab group and chemotherapy group, respectively) and patients with LDH greater than ULN at baseline (51% and 35%, respectively).
Baseline-karakteristika var velbalanceret mellem behandlingsgrupperne i den primære effekt- population og ITT-populationen.
Baseline characteristics were balanced between treatment groups in the primary efficacy population and the ITT population.
Baseline-LDH (E/l), median (min.; maks.)
Baseline LDH (U/L), median (, min, max)
Baseline-NS5A-RAV’ers indvirkning på helbredelsesrater
Impact of baseline NS5A RAVs on cure rates
Baseline-patientdemografi og sygdomskarakteristika var generelt balanceret mellem grupperne: den mediane alder var 61 år, 71 % af patienterne var mænd, 61 % var kaukasere, 35 % var asiater, ECOG PS var 0 for 39 % af patienterne og 1 for 61 % af patienterne, 81 % af patienterne havde målbar sygdom, 79 % af patienterne havde gastrisk cancer, mens 21 % havde adenokarcinom i den gastroøsofagale overgang (GEJ).
Baseline patient demographics and disease characteristics were generally balanced between arms: the median age was 61 years; 71% of patients were male; 61% were Caucasian, 35% Asian; the ECOG PS was 0 for 39% of patients, 1 for 61% of patients; 81% of patients had measurable disease and 79% had gastric cancer; 21% had GEJ adenocarcinoma.
Baseline-polymorfisme ved NS3-positionerne 43, 80, 122, 155, 156 og/eller 168, forbundet med nedsat aktivitet af simeprevir in vitro, var generelt ikke almindelige (1,3%) hos patienter med HCV- genotype 1-infektion (n = 2.007; puljede fase 2- og fase 3-studier med simeprevir i kombination med peginterferon alfa og ribavirin), bortset fra substitutionen Q80K hos patienter med HCV-genotype 1a, som blev observeret hos 30% af patienterne med HCV-genotype 1a og hos 0,5% af patienterne med HCV-genotype 1b.
Baseline polymorphisms at NS3 positions 43, 80, 122, 155, 156, and/or 168, associated with reduced simeprevir activity in vitro were generally uncommon (1.3%) in patients with HCV genotype 1 infection (n = 2,007; pooled phase 2 and phase 3 studies with simeprevir in combination with peginterferon alfa and ribavirin), with exception of the substitution Q80K in HCV genotype 1a patients which was seen 30% in patients with HCV genotype 1a and 0.5% in patients with HCV genotype 1b.
Baseline-respondenter, som fastholdt respons efter baseline, tillades som respondenter i analysen. e Inkluderer patienter (N), der opnåede eller fastholdt CHR (CP-patienter) eller, OHR(AP- og BP-patienter). f Inklusive patienter (N) med mindst 1 post-baseline hæmatologisk vurdering efter . g Inklusive patienter (N), der fik mindst en dosis Bosulif.
baseline responders who maintained response post-baseline to be responders. e Includes patients (N) who attained or maintained CHR for CP patients and OHR for AP and BP patients. f Including patients (N) with at least 1 post-baseline haematologic assessment. g Including patients (N) who received at least one dose of Bosulif.
Baseline-RNA-kategori
Baseline RNA category
Baseline-serostatus
Baseline Serostatus
Baseline-test efterfulgt af månedlig monitorering af komplette blodtal anbefales i de første 12 måneder af behandlingen og regelmæssigt efter dette tidspunkt for at monitorere for klinisk signifikante ændringer i et eller flere parametre under behandling, som kunne kræve afbrydelse af doseringen eller dosisreduktion og/eller yderligere behandling.
Baseline testing, followed by monthly monitoring of complete blood counts is recommended for the first 12 months of treatment and periodically after this time to monitor for clinically significant changes in any parameter during treatment which may require dose interruption or reduction and/or further treatment.
Baseline-variable, herunder kompleks cytogenetik er forbundet med progression til AML hos personer, som er transfusionsafhængige og har en Del (5q)-anomali.
Baseline variables including complex cytogenetics are associated with progression to AML in subjects who are transfusion dependent and have a Del (5q) abnormality.
Baseline-variable, herunder kompleks cytogenetik og TP53-mutation er forbundet med progression til AML hos personer, som er transfusionsafhængige og har en Del (5q)-anomali.
Baseline variables including complex cytogenetics and TP53 mutation are associated with progression to AML in subjects who are transfusion dependent and have a Del (5q) abnormality.
Baseline-VAS (mm)
Baseline VAS(mm)
Baseline-VAS(mm)
Baseline VAS(mm)
Baseline3
(11/11)
Baselinekarakteristika
Baseline characteristics
Baselinekarakteristika og behandlingsresultater for GS-US-236-0102 og GS-US-236-0103 er anført i hhv. tabel 3 og 4.
Baseline characteristics and treatment outcomes for both studies GS-US-236-0102 and GS-US-236-0103 are presented in Tables 3 and 4, respectively.
Baselinekarakteristika og behandlingsresultater til og med 96 uger for studie GS-US-183-0145 er anført i hhv. tabel 4 og 5.
Baseline characteristics and treatment outcomes through 96 weeks for study GS-US-183-0145 are presented in Tables 4 and 5 respectively.
Baselinekarakteristika og behandlingsresultater ved uge 48 og 144 for studie GS-US-216-0114 er anført i hhv. tabel 6 og 7.
Baseline characteristics and treatment outcomes at weeks 48 and 144 for study GS-US-216-0114 are presented in Tables 6 and 7, respectively.
Baselinekarakteristika og behandlingsvarighed med fondaparinux var sammenlignelige i de to UFH- grupper.
The baseline characteristics and duration of fondaparinux treatment were comparable in both UFH groups.
Baselinekarakteristika var velafbalancerede mellem de to arme.
Baseline characteristics were well balanced between the two arms.
Baselinetest, efterfulgt af månedlig monitorering, af komplet blodtælling anbefales i de første 12 måneders behandling og regelmæssigt derefter for at monitorere, om der sker klinisk signifikante ændringer i et eller flere parametre under behandlingen.
Baseline testing, followed by monthly monitoring, of complete blood counts is recommended for the first 12 months of treatment and periodically after this time to monitor for clinically significant changes in any parameter during treatment.
Baselineværdi (middel)
Baseline Value (Mean)
Baselineværdi Gennemsnit (SD) Min., maks.
Baseline value Mean (SD) Min, Max
Baselinie-antal af hvide blodlegemer (WBC) korrelerede ikke med udvikling af leukocytose under studien, og WBC-tal under konsolideringesterapien var ikke så høje som under induktion.
Baseline white blood cell (WBC) counts did not correlate with development of leukocytosis on study, and WBC counts during consolidation therapy were not as high as during induction.
baseres på klinisk respons, men
should be guided by clinical
baseres på klinisk respons.
be guided by clinical response.
Baseret herpå og og på de tilgængelige data besluttede udvalget, at fordelene ved Metalyse opvejer risiciene, og anbefalede udstedelse af en markedsføringstilladelse.
Based on this and all other available data, the Committee decided that Metalyse’s benefits are greater than its risks and recommended that it be given marketing authorisation.
Baseret på alle feltstudier er andelen af forebygget mastitis, ved behandling af hele besætningen med Imrestor, 0,25 (ætiologisk fraktion) (med 95 % konfidensinterval 0,14-0,35)
Based on all field studies, the proportion of mastitis prevented due to herd treatment with Imrestor (Prevented Fraction) is 0.25 (with 95% confidence interval 0.14 – 0.35).
Baseret på alle feltstudier er proportionen af mastitis forebygget ved behandling af hele besætningen med Imrestor (ætiologisk fraktion) 0,25 (med 95 % konfidensinterval 0,14-0,35).
Based on all field studies, the proportion of mastitis prevented due to herd treatment with Imrestor (Prevented Fraction) is 0.25 (with 95% confidence interval 0.14 – 0.35).
Baseret på alle studier har følgende procentdele af patienterne rapporteret om forbedring efter behandling med sildenafil: Psykogen erektil dysfunktion (84%), blandet erektil dysfunktion (77%), organisk erektil dysfunktion (68%), ældre (67%), diabetes mellitus (59%), iskæmisk hjertesygdom (69%), hypertension (68%), TURP (61%), radikal prostatektomi (43%), rygmarvsskade (83%), depression (75%).
Across all trials, the proportion of patients reporting improvement on sildenafil were as follows: psychogenic erectile dysfunction (84%), mixed erectile dysfunction (77%), organic erectile dysfunction (68%), elderly (67%), diabetes mellitus (59%), ischaemic heart disease (69%), hypertension (68%), TURP (61%), radical prostatectomy (43%), spinal cord injury (83%), depression (75%).
Baseret på analyse af præ- og post-dosis leverbiopsier fra mænd med Fabrys sygdom er halveringstiden i væv bestemt til at være over 24 timer, og hepatisk optagelse af enzymet er beregnet til at være 10% af den indgivne dosis.
Based on the analysis of pre- and post-dose liver biopsies in males with Fabry Disease, the tissue half- life has been estimated to be in excess of 24 hours and hepatic uptake of the enzyme estimated to be 10% of administered dose.
Baseret på analysen af de samlede placebo-kontrollerede kliniske studier, som i alt omfatter 1.307 Leganto- og 607 placebo-behandlede patienter, rapporterede 72,5% af patienterne i Leganto-gruppen og 58,0% af patienterne i placebo-gruppen mindst en bivirkning.
Based on the analysis of pooled placebo-controlled clinical trials comprising a total of 1,307 Leganto- and 607 placebo-treated patients, 72.5% of the patients on Leganto and 58.0% of patients on placebo reported at least one adverse reaction.
Baseret på analysen af de samlede placebo-kontrollerede kliniske studier, som i alt omfatter 1.307 Neupro- og 607 placebo-behandlede patienter, rapporterede 72,5% af patienterne i Neupro-gruppen og 58,0% af patienterne i placebo-gruppen mindst en bivirkning.
Based on the analysis of pooled placebo-controlled clinical trials comprising a total of 1,307 Neupro- and 607 placebo-treated patients, 72.5% of the patients on Neupro and 58.0% of patients on placebo reported at least one adverse reaction.
Baseret på analysen af de samlede placebo-kontrollerede kliniske studier, som i alt omfatter 748 Leganto- og 214 placebo-behandlede patienter, rapporterede 65,5% af patienterne i Leganto-gruppen og 33,2% af patienterne i placebo-gruppen mindst en bivirkning.
Based on the analysis of pooled placebo-controlled clinical trials comprising a total of 748 Leganto- and 214 placebo-treated patients, 65.5% of the patients on Leganto and 33.2% of patients on placebo reported at least one adverse reaction.
Baseret på antallet af patienter inkluderet i DUET-forsøgene kan sjældne og meget sjældne bivirkninger ikke påvises.
Rare and very rare ADRs cannot be detected based on the number of patients included in the DUET trials.
Baseret på AUC(0 – inf) udgjorde lenvatinib 60 % og 64 % af den totale radioaktivitet i hhv. plasma og blod.
Based on AUC(0 – inf), lenvatinib accounted for 60% and 64% of the total radioactivity in plasma and blood, respectively.